Piramal Critical Care Patent-Cliff Exposure & CMS Drug Spending Portfolio
Piramal Critical Care (Bethlehem, PA): 1 reconciled FDA prescription therapies, $11.0M 2024 CMS Part D & Medicaid spend, and $251 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | Bethlehem, PA |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $11.0M |
| 2024 Medicare Part D Spend | $131K |
| 2024 Medicaid Spend | $10.8M |
| California HCAI SB 17 Filings | Specialty launch notice ($251 intro WAC) |